Most hypertension cases take place with erythropoietin in conditions of severe renal impairment and with dialysis (Krapf and Hulter, 2009), while others of animals or human studies reporting the administration of erythropoietin with normal kidneys showed less advanced BP effects (Agarwal, 2018). Here, EPO is linked to hypertensive disorder.